TY - JOUR
T1 - Heart failure in chronic kidney disease
T2 - conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
AU - House, Andrew A.
AU - Wanner, Christoph
AU - Sarnak, Mark J.
AU - Piña, Ileana L.
AU - McIntyre, Christopher W.
AU - Komenda, Paul
AU - Kasiske, Bertram L.
AU - Deswal, Anita
AU - deFilippi, Christopher R.
AU - Cleland, John G.F.
AU - Anker, Stefan D.
AU - Herzog, Charles A.
AU - Cheung, Michael
AU - Wheeler, David C.
AU - Winkelmayer, Wolfgang C.
AU - McCullough, Peter A.
AU - Abu-Alfa, Ali K.
AU - Amann, Kerstin
AU - Aonuma, Kazutaka
AU - Appel, Lawrence J.
AU - Baigent, Colin
AU - Bakris, George L.
AU - Banerjee, Debasish
AU - Boletis, John N.
AU - Bozkurt, Biykem
AU - Butler, Javed
AU - Chan, Christopher T.
AU - Costanzo, Maria Rosa
AU - Dubin, Ruth F.
AU - Filippatos, Gerasimos
AU - Gikonyo, Betty M.
AU - Gikonyo, Dan K.
AU - Hajjar, Roger J.
AU - Iseki, Kunitoshi
AU - Ishii, Hideki
AU - Knoll, Greg A.
AU - Lenihan, Colin R.
AU - Lentine, Krista L.
AU - Lerma, Edgar V.
AU - Macedo, Etienne
AU - Mark, Patrick B.
AU - Noiri, Eisei
AU - Palazzuoli, Alberto
AU - Pecoits-Filho, Roberto
AU - Pitt, Bertram
AU - Rigatto, Claudio
AU - Rossignol, Patrick
AU - Setoguchi, Soko
AU - Sood, Manish M.
AU - Störk, Stefan
AU - Suri, Rita S.
AU - Szummer, Karolina
AU - Tang, Sydney C.W.
AU - Tangri, Navdeep
AU - Thompson, Aliza
AU - Vijayaraghavan, Krishnaswami
AU - Walsh, Michael
AU - Wang, Angela Yee Moon
AU - Weir, Matthew R.
N1 - Funding Information:
The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Abbott, Akebia Therapeutics, AMAG Pharmaceuticals, Amgen, AstraZeneca, Boehringer Ingelheim, Corvidia, Fresenius Medical Care, Keryx Biopharmaceuticals, NxStage, Relypsa, Roche, Sanifit, and Vifor Fresenius Medical Care Renal Pharma. We thank Jennifer King, PhD, for assistance with manuscript preparation.
Funding Information:
CW declared having received consultancy fees from Bayer, Boehringer Ingelheim, GSK, and Sanofi-Genzyme; speaker honoraria from AstraZeneca, Boehringer Ingelheim, Lilly, MSD, Novartis, and Sanofi-Genzyme; and research support from Sanofi-Genzyme. MJS declared having received research support from Akebia Therapeutics (monies paid to institution) and the National Institutes of Health. ILP declared having received consultancy fees from Relypsa; and research support from Food & Drug Administration, Center for Devices and Radiological Health. CWM declared having received consultancy fees from Baxter; and research support from Baxter, Canadian Institutes of Health Research, Heart and Stroke Foundation, Intellomed, and Kidney Foundation of Canada. PK declared having received consultancy fees from Boehringer Ingelheim; employment fees from Quanta Dialysis Technologies; and research support from Canadian Institutes of Health Research. AD declared having received speaker honoraria from PeerView Institute for Medical Education and research support from the National Institutes of Health. CRD declared having received consultancy fees from Abbott Diagnostics, Ortho Clinical, Roche Diagnostics, and Siemens; speaker honoraria from Roche Diagnostics; and research support from the National Institutes of Health. JGFC declared having received consultancy fees from AstraZeneca, Bayer, BMS, GSK, Medtronic, MyoKardia, Novartis, Philips, Sanofi, Servier, Stealth BioTherapeutics, Torrent Pharmaceuticals, and Vifor; speaker honoraria from AstraZeneca, BMS, GSK, Medtronic, MyoKardia, Novartis, Philips, Sanofi, Servier, Stealth BioTherapeutics, Torrent Pharmaceuticals, and Vifor; and research support from Amgen, Bayer, BMS, Medtronic, Novartis, Pharmacosmos, Pharma Nord, Stealth BioTherapeutics, Torrent Pharmaceuticals, and Vifor. SDA declared having received consultancy fees from Bayer, Boehringer Ingelheim, Novartis, Servier, and Vifor; speaker honoraria from Bayer, Boehringer Ingelheim, and Vifor; and research support from Abbott Vascular and Vifor. CAH declared having received consultancy fees from AbbVie, Amgen, AstraZeneca, Corvidia, DiaMedica, FibroGen, Janssen, Oxford University, OxThera, Pfizer, Relypsa, and Sanifit; stock equity from BMS, Boston Scientific, General Electric, Johnson & Johnson, and Merck; and research support from Amgen, BMS, CARSK (Canadian-Australasian Randomised Trial for Screening Kidney Transplant Recipients for Coronary Artery Disease), the National Heart, Lung, and Blood Institute, the National Institutes of Health, Relypsa, and Zoll. DCW declared having received consultancy fees from Akebia Therapeutics, AstraZeneca, Amgen, Boehringer Ingelheim, GSK, Janssen, and Vifor Fresenius; speaker honoraria from Amgen and Vifor Fresenius; and research support from AstraZeneca. WCW declared having received consultancy fees from Akebia Therapeutics, AMAG, Amgen, AstraZeneca, Bayer, Daichii-Sankyo, Relypsa, and ZS Pharma; speaker honoraria from FibroGen; and research support from the National Institutes of Health. All the other authors declared no competing interests.
Funding Information:
The conference was sponsored by KDIGO and supported in part by unrestricted educational grants from Abbott, Akebia Therapeutics, AMAG Pharmaceuticals, Amgen, AstraZeneca, Boehringer Ingelheim, Corvidia, Fresenius Medical Care, Keryx Biopharmaceuticals, NxStage, Relypsa, Roche, Sanifit, and Vifor Fresenius Medical Care Renal Pharma. We thank Jennifer King, PhD, for assistance with manuscript preparation.
Publisher Copyright:
© 2019 The Authors
PY - 2019/6
Y1 - 2019/6
N2 - The incidence and prevalence of heart failure (HF) and chronic kidney disease (CKD) are increasing, and as such a better understanding of the interface between both conditions is imperative for developing optimal strategies for their detection, prevention, diagnosis, and management. To this end, Kidney Disease: Improving Global Outcomes (KDIGO) convened an international, multidisciplinary Controversies Conference titled Heart Failure in CKD. Breakout group discussions included (i) HF with preserved ejection fraction (HFpEF) and nondialysis CKD, (ii) HF with reduced ejection fraction (HFrEF) and nondialysis CKD, (iii) HFpEF and dialysis-dependent CKD, (iv) HFrEF and dialysis-dependent CKD, and (v) HF in kidney transplant patients. The questions that formed the basis of discussions are available on the KDIGO website http://kdigo.org/conferences/heart-failure-in-ckd/, and the deliberations from the conference are summarized here.
AB - The incidence and prevalence of heart failure (HF) and chronic kidney disease (CKD) are increasing, and as such a better understanding of the interface between both conditions is imperative for developing optimal strategies for their detection, prevention, diagnosis, and management. To this end, Kidney Disease: Improving Global Outcomes (KDIGO) convened an international, multidisciplinary Controversies Conference titled Heart Failure in CKD. Breakout group discussions included (i) HF with preserved ejection fraction (HFpEF) and nondialysis CKD, (ii) HF with reduced ejection fraction (HFrEF) and nondialysis CKD, (iii) HFpEF and dialysis-dependent CKD, (iv) HFrEF and dialysis-dependent CKD, and (v) HF in kidney transplant patients. The questions that formed the basis of discussions are available on the KDIGO website http://kdigo.org/conferences/heart-failure-in-ckd/, and the deliberations from the conference are summarized here.
KW - cardiovascular disease
KW - chronic kidney disease
KW - congestive heart failure
KW - hemodialysis
KW - transplantation
UR - http://www.scopus.com/inward/record.url?scp=85064905834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064905834&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2019.02.022
DO - 10.1016/j.kint.2019.02.022
M3 - Article
C2 - 31053387
AN - SCOPUS:85064905834
SN - 0085-2538
VL - 95
SP - 1304
EP - 1317
JO - Kidney international
JF - Kidney international
IS - 6
ER -